These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 27446497)

  • 1. High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers.
    Hettich M; Braun F; Bartholomä MD; Schirmbeck R; Niedermann G
    Theranostics; 2016; 6(10):1629-40. PubMed ID: 27446497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
    Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
    J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.
    Natarajan A; Mayer AT; Reeves RE; Nagamine CM; Gambhir SS
    Mol Imaging Biol; 2017 Dec; 19(6):903-914. PubMed ID: 28247187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes.
    Natarajan A; Mayer AT; Xu L; Reeves RE; Gano J; Gambhir SS
    Bioconjug Chem; 2015 Oct; 26(10):2062-9. PubMed ID: 26307602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
    Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z
    Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-Specific Immuno-PET Tracer to Image PD-L1.
    Wissler HL; Ehlerding EB; Lyu Z; Zhao Y; Zhang S; Eshraghi A; Buuh ZY; McGuth JC; Guan Y; Engle JW; Bartlett SJ; Voelz VA; Cai W; Wang RE
    Mol Pharm; 2019 May; 16(5):2028-2036. PubMed ID: 30875232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
    Chatterjee S; Lesniak WG; Gabrielson M; Lisok A; Wharram B; Sysa-Shah P; Azad BB; Pomper MG; Nimmagadda S
    Oncotarget; 2016 Mar; 7(9):10215-27. PubMed ID: 26848870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
    Wang Y; Wu L; Tian C; Zhang Y
    Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid PD-L1 detection in tumors with PET using a highly specific peptide.
    Chatterjee S; Lesniak WG; Miller MS; Lisok A; Sikorska E; Wharram B; Kumar D; Gabrielson M; Pomper MG; Gabelli SB; Nimmagadda S
    Biochem Biophys Res Commun; 2017 Jan; 483(1):258-263. PubMed ID: 28025143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immuno-PET Imaging of
    Li D; Cheng S; Zou S; Zhu D; Zhu T; Wang P; Zhu X
    Mol Pharm; 2018 Apr; 15(4):1674-1681. PubMed ID: 29502426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy.
    Broos K; Lecocq Q; Raes G; Devoogdt N; Keyaerts M; Breckpot K
    Theranostics; 2018; 8(13):3559-3570. PubMed ID: 30026866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 is an activation-independent marker of brown adipocytes.
    Ingram JR; Dougan M; Rashidian M; Knoll M; Keliher EJ; Garrett S; Garforth S; Blomberg OS; Espinosa C; Bhan A; Almo SC; Weissleder R; Lodish H; Dougan SK; Ploegh HL
    Nat Commun; 2017 Sep; 8(1):647. PubMed ID: 28935898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma.
    Wen X; Shi C; Zhao L; Yao L; Xu D; Lin X; Su X; Liu T; Zhuang R; Lin Q; Chen H; Guo Z; Zhang X
    Nucl Med Biol; 2020; 86-87():44-51. PubMed ID: 32474281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1/PD-L1 Pathway in Breast Cancer.
    Schütz F; Stefanovic S; Mayer L; von Au A; Domschke C; Sohn C
    Oncol Res Treat; 2017; 40(5):294-297. PubMed ID: 28346916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb.
    Uehara J; Ohkuri T; Kosaka A; Ishibashi K; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Ishida-Yamamoto A; Kobayashi H
    Biochem Biophys Res Commun; 2017 Aug; 490(2):521-527. PubMed ID: 28624449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab).
    Gill AL; Green SA; Abdullah S; Le Saout C; Pittaluga S; Chen H; Turnier R; Lifson J; Godin S; Qin J; Sneller MC; Cuillerot JM; Sabzevari H; Lane HC; Catalfamo M
    AIDS; 2016 Oct; 30(16):2487-2493. PubMed ID: 27490642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma.
    Nedrow JR; Josefsson A; Park S; Ranka S; Roy S; Sgouros G
    J Nucl Med; 2017 Oct; 58(10):1560-1566. PubMed ID: 28522738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PD1/PD-L1 immunohistochemistry in thoracic oncology: Where are we?].
    Hofman P; Ilié M; Lassalle S; Long E; Bence C; Butori C; Hofman V
    Ann Pathol; 2017 Feb; 37(1):39-45. PubMed ID: 28159404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1/PD-L1 expression in extra-medullary lesions of multiple myeloma.
    Crescenzi A; Annibali O; Bianchi A; Pagano A; Donati M; Grifoni A; Avvisati G
    Leuk Res; 2016 Oct; 49():98-101. PubMed ID: 27619200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.